TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05530694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician communication training
Description: The clinician training is a generic, skills- and attitude-based approach for clinicians to acknowledge their decision making conversations with patients that 1) there is more than one option, and 2) patient's views matter in deciding what to do next. This tools-free approach can be used on the spot when needed and is termed fostering choice awareness (FCA). The one-hour training consists of 4 parts: 1) a knowledge session on evidence and guidelines on effective conversations and SDM, 2) video-review of behaviors which foster or hinder choice awareness, 3) clinical simulations in which clinicians practice fostering choice awareness behaviors, and 4) a reminder card for use in future clinic visits. Video clips will be of patient-clinician conversations around treatment decision making to prompt and probe clinicians' experiences, improve understanding, and improve practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient activation
Description: The patient activation component consists of three questions patients can ask their clinician to help them become more involved: 1. What are my options?; 2. What are the possible benefits and harms of those options?; 3. How likely are each of those benefits and harms to happen to me? These questions have been used in studies to promote improved communication in a number of conditions including cardiovascular disease, cancer, and women's health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RA Medication summary guide and RA Choice
Description: RA Choice presents information on FDA-approved RA treatments in a set of cards, which can be used alone or in combination based on a patient's preference, values, and the clinician's experience. The RA medication summary guide describes options for medication, physical therapy, occupational therapy, and ways to stay healthy with diet and exercise. Tool development followed key principles of creating low literacy materials that featured icons, short phrases written in plain language, and included topics of interest to RA patients faced with a medication decision. For the proposed study, we will include a paper-based version of the tool, or a web-based version available for telephone or VA Video Connect (VVC) visits. The tools will be updated to include new FDA-approved therapies (e.g., JAK inhibitors).
Study: NCT05979415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine Cartridge
Description: Staccato Cartridge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apomorphine Cartridge
Description: Staccato Cartridge
Study: NCT05348304

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EUDIAMET
Description: A combination of myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
Study: NCT06397300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral Ultrasound guided erector spinae plane (ESP) block
Description: To perform ESP block in the lateral position bilaterally ,the skin will be disinfected with 70% alchol bilaterally and a linear transducer is placed in a longitudinal parasagittal orientation and erector spinae muscle, trapezius muscle, rhomboid major muscle (rhomboid major muscle is absent below T6 level) and transverse process are visualized and local anesthetic is injected (0.25% bupivacaine 20 ml in each side) in the area between transverse process and erector spinae muscle at T10 level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum block
Description: In the lateral decubitus position. Right block will be performed; the patient will then repositioned for the left block. An ultrasound device with a convex probe (5-8 MHz) will be placed in the mid-axillary line just above the iliac crest. Then, scan dorsally to keep the transverse orientation until seeing the aponeurosis of the transverses abdominus muscle and by following this aponeurosis, QL muscle will be visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle. A spinal needle (20G) will be inserted in-plane from the anterior to posterior direction, and the tip of the needle will be advanced anterior to the QL muscle. The target site for injection is the plane between the quadratus lumborum and psoas major muscles. This will be followed by injection of 0.25% bupivacaine 20 ml in each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar epidural
Description: under strict aseptic precautions, lumbar epidural was performed for patients in Group III using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces was chosen for the injection.~The epidural space identified by the loss of resistance technique. The catheter was advanced 4 cm cephalad. When the aspiration test results for blood and cerebrospinal fluid were negative, a test dose of (3 mL) 2% lidocaine with 1: 200,000 adrenaline was given after the placement of the epidural catheter.~Then this will be followed by injection of 0.25% bupivacaine 15 ml as a single injection after induction of general anesthesia.
Study: NCT06487117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huafu Shengji Ointment
Description: Huafu Shengji Ointment~1. The experimental group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The experimental group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, Huafu Shengji Ointment is applied topically with a coverage thickness of 1mm, followed by sterile gauze dressing. The dressing is changed every other day. The treatment period is 4-8 weeks.
Study: NCT05016596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: turmeric
Description: Turmeric supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT06027515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program
Description: Multimodal prehabilitation program consisting of pre-surgical optimization of nutrition, physical function, and sleep health via individualized plans. Participants will also be supplied with Nestle Impact Advances Recovery Immunonutrition Drink.
Study: NCT06173284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: subcutaneous injection
Study: NCT05502029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended translation
Description: Translation extended beyond the preoperative area

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard translation
Description: Translation in the preoperative area
Study: NCT06524115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator device, Closed-field autorefractometer without cycloplegia
Description: Objective refraction without cycloplegia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distance visual acuity check using objective refraction without cycloplegia
Description: Distance visual acuity is checked, using objective refraction without cycloplegia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator device, Closed-field autorefractometer with cycloplegia
Description: Objective refraction with cycloplegia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distance visual acuity check using objective refraction with cycloplegia
Description: Distance visual acuity is checked, using objective refraction with cycloplegia
Study: NCT05029531

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
Description: two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
Study: NCT05786859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg
Description: Rifaximin Treatment Group:on the basis of comprehensive treatment of liver failure, Rifaximin will be added, three times a day, 400mg each time, for a total of 4 weeks, and we will observe until 12 weeks after withdrawal.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Treatment without Rifaximin
Description: The standard treatment group (control group), which will receive routine comprehensive treatment for liver failure without Rifaximin.
Study: NCT05974761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: The patient was placed in a lateral decubitus position with the physician standing on the ventral side of the patient, with the crotch resting on the anterior edge of the superior iliac crest, and the elbow rising from the medial side of the highest point of the superior iliac crest, follow the palpation (avoiding the L3 transverse process) along the steep edge of the skeleton slowly toward the spine, and focus on the painful points or cords by repeatedly applying the elbow press method and the elbow flick method for 1-2 minutes, and then the elbow tip contact to find the sinew knot and along the vertical direction of 3-5 times, the force should be deep penetration.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Chinese massage
Description: Through the point, massage, bone-setting treatment
Study: NCT06167057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin/Gemcitabine
Description: UTUC treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: UTUC treatment
Study: NCT06487117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethacridine lactate solution
Description: ethacridine lactate solution~1. The control group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The control group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, the wound is cleaned and disinfected with ethacridine lactate solution, then covered and dressed with sterile gauze. The dressing is changed every other day. The treatment period is 4-8 weeks.
Study: NCT04881643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioural therapy via a digital support
Description: A blended treatment approach to PTSD, blending internet-based CBT with face-to-face sessions with a therapist
Study: NCT05788263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuroscience based aproach
Description: exercise for pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuroscience based aproach
Description: exercise for pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuroscience based aproach
Description: exercise for pain
Study: NCT06399159

Intervention type: PROCEDURE
Intervention: Thyroidectomy and lymph node dissection
Description: All surgical specimens of thyroidectomy and lymph node dissection were subjected to paraffin-embedded histopathological examination, and postoperative were categorized as with cervical lymph node metastasis and without cervical lymph node metastasis.

Intervention type: PROCEDURE
Intervention: Thyroidectomy and lymph node dissection
Description: All surgical specimens of thyroidectomy and lymph node dissection were subjected to paraffin-embedded histopathological examination, and postoperative were categorized as with cervical lymph node metastasis and without cervical lymph node metastasis.
Study: NCT04690777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: VESTIBULAR EXERCISE
Description: OCULAR AND MOVEMENT EXERCISES

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: VESTIBULAR EXERCISE
Description: OCULAR AND MOVEMENT EXERCISES

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MULTICOMPONENT EXERCISE
Description: exercises includes strengthening, cardiovascular training, flexibility and balance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MULTICOMPONENT EXERCISE
Description: exercises includes strengthening, cardiovascular training, flexibility and balance
Study: NCT06012227

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: kent'erbas cheese study
Description: Nutritional intervention with kent'erbas pecorino from extensive farming with crossover and industrial pecorino from intensive farming

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: kent'erbas cheese study
Description: Nutritional intervention with kent'erbas pecorino from extensive farming with crossover and industrial pecorino from intensive farming
Study: NCT04905342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805
Description: orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1805-R1and NVP-1805-R2
Description: orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
Study: NCT06262984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Play
Description: The researcher will demonstrate the nasopharyngeal swabbing process on the doll with the children who have chosen a therapeutic play group, using a therapeutic play method, and play with the child. The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
Study: NCT05016960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep-SMART
Description: Sleep-SMART will be a treatment for insomnia that will follow the standard 6 session 50-minute CBT-I format and will deliver CBT-I treatment along with training in select CogSMART strategies to enhance intervention learning and adherence. It will be delivered via video-based telehealth.
Study: NCT06258252

Intervention type: OTHER
Intervention: Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
Description: Effect of BCAAs metabolic dysfunction on cardiac function in sepsis

Intervention type: OTHER
Intervention: Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
Description: Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
Study: NCT05220423

Intervention type: OTHER
Group type: OTHER
Intervention: sms and emails reminders
Description: 6 reminders encouraging influenza vaccination on top of the National annual communication campaign organized by the French Health System authorities

Intervention type: OTHER
Group type: OTHER
Intervention: No reminders
Description: no reminders on top of the National annual communication campaign organized by the French Health System authorities
Study: NCT05635617

Intervention type: PROCEDURE
Intervention: Lower Extremity Surgery
Description: Patients 18 years of age or older with high energy lower extremity fractures. Provision of informed consent.
Study: NCT06155435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solution focused approach training
Description: To the woman; A list of education subjects will be sent in order to determine educational changes for birth, birth and postpartum periods. This list will be; It consists of reproductive organs, pregnancy formations, changes, psychological changes, daily life, nutrition, reproductive monitoring, immunization, frequent problems and solution suggestions, danger signs and what to do. Also included in the list are labor, birth cycle, and postpartum periods.
Study: NCT04325880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 50 MG
Description: Patients in this arm will receive Mirabegrone 50 MG once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Patients in this arm will receive Tamsulosin o.4 MG once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 10 MG
Description: Patients in this arm will receive Solifenacin Succinate 10 MG once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patients in this arm will receive placebo oral tablet once daily
Study: NCT05662969

Intervention type: DEVICE
Intervention: MACHINE PERFUSION
Description: Different outcomes of MP use in low/mid-volume and high-volume LT centres

Intervention type: DEVICE
Intervention: MACHINE PERFUSION
Description: Different outcomes of MP use in low/mid-volume and high-volume LT centres
Study: NCT04404777

Intervention type: PROCEDURE
Intervention: Treatment for local recurrence with surgery or other treatments
Description: All types of treatment for local recurrence will be evaluated
Study: NCT05888519

Intervention type: OTHER
Group type: OTHER
Intervention: FID123300 ocular lubricant
Description: Investigational ocular lubricant

Intervention type: OTHER
Group type: OTHER
Intervention: FID123300 ocular lubricant
Description: Investigational ocular lubricant

Intervention type: OTHER
Group type: OTHER
Intervention: FID123300 ocular lubricant
Description: Investigational ocular lubricant

Intervention type: OTHER
Group type: OTHER
Intervention: FID123301 ocular lubricant
Description: Investigational ocular lubricant

Intervention type: OTHER
Group type: OTHER
Intervention: FID123301 ocular lubricant
Description: Investigational ocular lubricant

Intervention type: OTHER
Group type: OTHER
Intervention: FID123301 ocular lubricant
Description: Investigational ocular lubricant

Intervention type: OTHER
Group type: OTHER
Intervention: FID122505 ocular lubricant
Description: Comparator ocular lubricant

Intervention type: OTHER
Group type: OTHER
Intervention: FID122505 ocular lubricant
Description: Comparator ocular lubricant

Intervention type: OTHER
Group type: OTHER
Intervention: FID122505 ocular lubricant
Description: Comparator ocular lubricant
Study: NCT06551545

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tryptophan intake
Description: There are 5 different tryptophan test intake levels ranging from 2, 3, 4.5, 6, 8 mg.kg-1.day.1
Study: NCT05902624

Intervention type: DRUG
Group type: OTHER
Intervention: Hepatitis B Virus Vaccine(HBV)
Description: Hepatitis B Virus Vaccine(HBV)

Intervention type: DRUG
Group type: OTHER
Intervention: Hepatitis B Virus Vaccine(HBV)
Description: Hepatitis B Virus Vaccine(HBV)

Intervention type: DRUG
Group type: OTHER
Intervention: Hepatitis B Virus Vaccine(HBV)
Description: Hepatitis B Virus Vaccine(HBV)
Study: NCT06369064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVHD Dialysis parameters
Description: In the CVVHD group, patients will receive a dialysis dose of 25ml/kg/h dialysate (100% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²).Regional anticoagulation with citrate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CVVHDF Dialysis parameters
Description: In the CVVHD group, patients will receive a dialysis dose of 25ml/kg/h dialysate (50% ultrafiltration, 50% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²). Systemic anticoagulation with heparine
Study: NCT04941872

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT
Description: Each subject receive a single intravenous injection of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
Study: NCT05029284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: teleABLE
Description: Participants will be guided to self-monitor their daily activities, schedule personally meaningful non-sedentary activities, collaboratively problem solve to overcome barriers to the activity, and self-assess their progress. Participants may be asked to self-monitor their activity levels and complete planned activities between sessions.
Study: NCT05540431

Intervention type: DRUG
Group type: OTHER
Intervention: Activated Charcoal
Description: RCT

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic
Description: RCT

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: RCT
Study: NCT05684770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4G tablet
Description: Participants will receive for the whole period of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.
Study: NCT05761847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Medication Therapy Management (pMTM)
Description: The pMTM intervention is comprised of 3 activities: comprehensive review of the medication regimen; optimization of the medication regimen; and creation of the medication action plan.
Study: NCT06366789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134
Description: oral capsules QD
Study: NCT05877989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid
Description: Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid
Description: Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.